Breast Cancer Clinical Trials in Georgia

Showing 461-480 of 660 trials

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

NCT00093145

This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.

Breast Cancer

Celgene32 participantsStarted Jun 2004

Long Beach, California, United States • Stamford, Connecticut, United States • Washington D.C., District of Columbia, United States +11 more locations

COMPLETEDPhase 265 miles

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT02441946

The purpose of this study is to evaluate the biological effects of abemaciclib in combination with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone in the tumors of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.

Breast CancerHormone Receptor Positive TumorEarly-Stage Breast Carcinoma

Eli Lilly and Company224 participantsStarted Aug 2015

Bakersfield, California, United States • La Jolla, California, United States • Los Angeles, California, United States +63 more locations

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Breast Cancer Trials in Other Cities

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Vaccine Therapy in Treating Patients With Breast Cancer

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

MRI to Detect Breast Tumors in Women

MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Combination Chemotherapy in Treating Patients With Breast Cancer

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Other Conditions in Georgia